1.Icodextrin and spurious hyperglycemia in peritoneal dialysis patients: a hospital-wide attempt to prevent such errors.
Korean Journal of Anesthesiology 2017;70(4):479-479
No abstract available.
Humans
;
Hyperglycemia*
;
Peritoneal Dialysis*
2.Effect of nutritional status on transdermal fentanyl absorption in cancer patients
Tomohiko Tairabune ; Hiroaki Takahashi ; Takeshi Chiba ; Atsuko Sugawara ; Yusuke Kimura ; Kenzo Kudo ; Go Wakabayashi ; Katsuo Takahashi
Palliative Care Research 2012;7(2):395-402
Objective: This study aimed to investigate the effect of nutritional status on estimated fentanyl absorption in cancer patients being treated with a fentanyl transdermal patch (FP), by measuring the residual fentanyl content in used patches. Methods: 24 adult Japanese inpatients receiving FP treatment for chronic cancer-related pain were enrolled. During FP application, the nutritional risk of the patients was measured using the Malnutrition Universal Screening Tool (MUST) and Nutritional Risk Screening 2002 (NRS 2002), both of which are nutrition screening tools used widely in Japan. We then classified the patients into low-, medium-, and high-risk groups according to the nutritional risk measured by MUST, and compared the transdermal fentanyl delivery efficiency (FE) between that groups. Results: The FE, which is estimated by the residual fentanyl content in used FPs collected from the patients, was found to be decreased in the high-risk group. According to NRS 2002, the mean transdermal fentanyl delivery efficiency in the high-risk group was significantly lower than that in the low-risk group. Conclusion: These results showed that changes in nutritional status affect FE, and that poor nutritional status might decrease transdermal fentanyl absorption in cancer patients.
3.Electroconvulsive Therapy for Parkinson’s Disease with Depression and Neuroleptic Malignant Syndrome: A Case Report
Yuhei MORI ; Itaru MIURA ; Michinari NOZAKI ; Yusuke OSAKABE ; Ryuta IZUMI ; Takahiro AKAMA ; So KIMURA ; Hirooki YABE
Clinical Psychopharmacology and Neuroscience 2021;19(3):572-575
Parkinson’s disease is often complicated by psychiatric symptoms. Psychiatrists are caught in a dilemma between such symptoms and physical treatment since Parkinson’s disease sometimes shows treatment resistance based on pharmacological treatment-induced dopamine dysfunction. Here, we report on a 64-year-old woman with a 15-year history of Parkinson’s disease with stage IV severity based on the Hoehn and Yahr scale. She was admitted to our hospital with a diagnosis of major depressive disorder with psychotic features. Unfortunately, her treatment course for depression was complicated by neuroleptic malignant syndrome. Because we were concerned about the persistence of her depressive symptoms, the risk of psychotropic drugs causing adverse effects, and progressive disuse syndrome, we administered modified electroconvulsive therapy. Her symptoms of neuroleptic malignant syndrome and depression sufficiently improved after five sessions of modified electroconvulsive therapy. Additionally, the primary motor symptoms of her Parkinson’s disease also markedly improved. The improvement of neuroleptic malignant syndrome and her motor symptoms based on dopamine dysfunction can be explained by electroconvulsive therapy’s effectiveness in activating dopamine neurotransmission. Besides, the marked improvement of her depressive episode with psychotic features was presumed to involve dopamine receptor activation and regulation. Because advanced Parkinson’s disease can sometimes be refractory to treatment based on pharmacological treatment-induced dopamine dysfunction, psychiatrists often have difficulty treating psychiatric symptoms; electroconvulsive therapy may stabilize the dopaminergic system in such cases, presenting a possible non-pharmacologic treatment option for Parkinson’s disease.
4.Electroconvulsive Therapy for Parkinson’s Disease with Depression and Neuroleptic Malignant Syndrome: A Case Report
Yuhei MORI ; Itaru MIURA ; Michinari NOZAKI ; Yusuke OSAKABE ; Ryuta IZUMI ; Takahiro AKAMA ; So KIMURA ; Hirooki YABE
Clinical Psychopharmacology and Neuroscience 2021;19(3):572-575
Parkinson’s disease is often complicated by psychiatric symptoms. Psychiatrists are caught in a dilemma between such symptoms and physical treatment since Parkinson’s disease sometimes shows treatment resistance based on pharmacological treatment-induced dopamine dysfunction. Here, we report on a 64-year-old woman with a 15-year history of Parkinson’s disease with stage IV severity based on the Hoehn and Yahr scale. She was admitted to our hospital with a diagnosis of major depressive disorder with psychotic features. Unfortunately, her treatment course for depression was complicated by neuroleptic malignant syndrome. Because we were concerned about the persistence of her depressive symptoms, the risk of psychotropic drugs causing adverse effects, and progressive disuse syndrome, we administered modified electroconvulsive therapy. Her symptoms of neuroleptic malignant syndrome and depression sufficiently improved after five sessions of modified electroconvulsive therapy. Additionally, the primary motor symptoms of her Parkinson’s disease also markedly improved. The improvement of neuroleptic malignant syndrome and her motor symptoms based on dopamine dysfunction can be explained by electroconvulsive therapy’s effectiveness in activating dopamine neurotransmission. Besides, the marked improvement of her depressive episode with psychotic features was presumed to involve dopamine receptor activation and regulation. Because advanced Parkinson’s disease can sometimes be refractory to treatment based on pharmacological treatment-induced dopamine dysfunction, psychiatrists often have difficulty treating psychiatric symptoms; electroconvulsive therapy may stabilize the dopaminergic system in such cases, presenting a possible non-pharmacologic treatment option for Parkinson’s disease.
5.Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience.
Takuya YOSHINO ; Minoru MATSUURA ; Naoki MINAMI ; Satoshi YAMADA ; Yusuke HONZAWA ; Masamichi KIMURA ; Yorimitsu KOSHIKAWA ; Ali MADIAN ; Takahiko TOYONAGA ; Hiroshi NAKASE
Intestinal Research 2015;13(3):266-273
BACKGROUND/AIMS: Early use of biologics in patients with Crohn's disease (CD) improves quality of life. However, the effects of the early use of immunomodulators on long-term outcomes remain unclear. This study aimed to evaluate the effects of immunomodulators in patients with CD. METHODS: Between January 2004 and December 2011, 47 biologic-naive CD patients treated with thiopurines alone for remission maintenance were analyzed. The patients were classified into 2 groups depending on the presence or absence of digestive complications. We evaluated the efficacy of and predictive factors for thiopurine use for remission maintenance. RESULTS: The cumulative relapse rates at 24 and 60 months were 13.7% and 35.4%, respectively. Regarding patient characteristics, there was a significant difference in patient history of surgery between the non-relapse and relapse groups (P=0.021). The cumulative relapse rate was lower in patients without a history of surgery than in those with such a history (27.2% and 52.9% at 60.0 months, respectively). Multivariate analysis suggested that the prevalence of stricturing and penetrating complications is an independent factor for relapse. The cumulative relapse rate in patients without a history of surgery was significantly lower in the non-stricturing and non-penetrating group than in the stricturing and penetrating group (11.8% at 85.0 months vs. 58.5% at 69.0 months; P=0.036). CONCLUSIONS: Thiopurine use might be beneficial for the long-term maintenance of remission in biologic-naive Crohn's disease patients without digestive complications and a history of surgery.
Asian Continental Ancestry Group*
;
Biological Products
;
Crohn Disease*
;
Humans
;
Immunologic Factors
;
Multivariate Analysis
;
Prevalence
;
Quality of Life
;
Recurrence
6.Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis.
Satoshi YAMADA ; Takuya YOSHINO ; Minoru MATSUURA ; Masamichi KIMURA ; Yorimitsu KOSHIKAWA ; Naoki MINAMI ; Takahiko TOYONAGA ; Yusuke HONZAWA ; Hiroshi NAKASE
Intestinal Research 2015;13(3):250-258
BACKGROUND/AIMS: The long-term clinical outcomes of patients with bio-naive ulcerative colitis (UC) who maintain remission with thiopurine are unclear. The aim of this study was to assess the long-term efficacy and safety of maintenance treatment with thiopurine in UC patients. METHODS: This was a retrospective observational cohort analysis conducted at a single center. Between December 1998 and August 2013, 59 of 87 patients with bio-naive UC who achieved remission after induction with treatments other than biologics were enrolled. Remission maintenance with thiopurine was defined as no concomitant treatment needed other than 5-aminosalicylate without relapse. We assessed the remission-maintenance rate, mucosal healing rate, colectomy-free rate, and treatment safety in UC patients who received thiopurine as maintenance treatment. RESULTS: The 84-month cumulative remission-maintenance and colectomy-free survival rates in the UC patients who were receiving maintenance treatment with thiopurine and 5-aminosalicylate were 43.9% and 88.0%, respectively. Of the 38 patients who underwent colonoscopy during thiopurine maintenance treatment, 23 (60.5%) achieved mucosal healing. Of the 59 patients who achieved clinical remission with thiopurine, 6 patients (10.2%) discontinued the thiopurine therapy because of adverse events. CONCLUSIONS: Our study demonstrates the long-term efficacy and safety of thiopurine treatment in patients with bio-naive UC.
Asian Continental Ancestry Group*
;
Biological Products
;
Cohort Studies
;
Colitis, Ulcerative*
;
Colonoscopy
;
Humans
;
Mesalamine
;
Recurrence
;
Retrospective Studies
;
Survival Rate
7.Quadricuspid Aortic Valve Complicated with Severe Aortic Regurgitation and Left-Sided Inferior Vena Cava.
Jun SHIRAISHI ; Kazunari OKAWA ; Kohei MUGURUMA ; Daisuke ITO ; Masayoshi KIMURA ; Eigo KISHITA ; Yusuke NAKAGAWA ; Masayuki HYOGO ; Akiyuki TAKAHASHI ; Takahisa SAWADA
Journal of Cardiovascular Ultrasound 2017;25(1):34-37
No abstract available.
Aortic Valve Insufficiency*
;
Aortic Valve*
;
Echocardiography, Transesophageal
;
Vena Cava, Inferior*
8.Influence of body fat in cancer patients on residual content of used fentanyl matrix patches
Takeshi Chiba ; Yusuke Kimura ; Hiroaki Takahashi ; Tomohiko Tairabune ; Yoshiaki Nagasawa ; Kaoru Mori ; Yuji Yonezawa ; Atsuko Sugawara ; Sachiko Kawaguchi ; Hidenobu Kawamura ; Satoshi Nishizuka ; Kenzo Kudo ; Kunihiko Fujiwara ; Kenichiro Ikeda ; Go Wakabayashi ; Katsuo Takahashi
Palliative Care Research 2010;5(2):206-212
Purpose: The objective of this study was to investigate whether body fat rate (BFR) and triceps skinfold thickness (TSF) are associated with estimated fentanyl absorption in patients treated with the fentanyl transdermal matrix patch for moderate to severe cancer pain, by measuring the residual content of fentanyl in used matrix patches. Methods: Adult Japanese inpatients experiencing chronic cancer-related pain and receiving treatment for the first time with a transdermal fentanyl matrix patch (Durotep®MT patch) were included in the present study. During the initial application period, BFR was measured using a body fat scale, and TSF was measured by an experienced nurse with an adipometer. One patch was collected from each patient. The residual fentanyl content in used matrix patch was determined by high-performance liquid chromatography. The transdermal fentanyl delivery efficiency was estimated based on the fentanyl content of the used matrix patches. Results: Fifteen adult patients (5 males and 10 females) were included in this study. Nine patches with a release rate of 12.5μg/h and 6 patches with a release rate of 25μg/h were collected. The application site was the chest or upper arm. BFR and TSF both showed a significant positive correlation with delivery efficiency. Conclusion: In malnourished or low-body fat patients receiving DMP, pain intensity should be more carefully monitored, and fentanyl dose adjustment may be required. Additional parameters, such as nutritional status including body fat change, the degree of dry skin, and plasma fentanyl concentration, also require detailed evaluation. Palliat Care Res 2010; 5(2): 206-212
9.Are Newer Extracorporeal Shock Wave Lithotripsy Models Truly Improving Pancreatolithiasis Lithotripsy Performance? A Japanese Single-Center Study Using Endoscopic Adjunctive Treatment
Ken ITO ; Naoki OKANO ; Kensuke TAKUMA ; Susumu IWASAKI ; Koji WATANABE ; Yusuke KIMURA ; Yuto YAMADA ; Kensuke YOSHIMOTO ; Seiichi HARA ; Yui KISHIMOTO ; Takahisa MATSUDA ; Yoshinori IGARASHI
Gut and Liver 2023;17(4):647-658
Background/Aims:
Many Japanese institutions use electromagnetic extracorporeal shock wave lithotripsy (ESWL) systems for treating pancreatic duct stones. However, there are no reports on direct comparisons between recent electromagnetic lithotripters. This study aimed to verify whether the new electromagnetic lithotripter can improve the efficiency of pancreatic stone fragmentation, and to clarify the role of combined endoscopic treatment on the clearance of pancreatic duct stones.
Methods:
We retrospectively identified 208 patients with pancreatolithiasis who underwent endoscopic adjunctive treatment after pancreatic ESWL at a single Japanese center over a 17-year period. We evaluated the outcome data of this procedure performed with SLX-F2 (last 2 years; group A) and Lithostar/Lithoskop (first 15 years; group B), as well as additional endoscopic treatments for pancreatolithiasis. We also performed logistic regression analysis to detect various factors associated with the procedure.
Results:
For pancreatic head stones, ESWL disintegration was achieved in 93.7% of group A patients and 69.0% of group B patients (p=0.004), and adjunctive endoscopic treatment removed stones in 96.8% of group A patients and 73.0% of group B patients (p=0.003). Multivariate analysis revealed that lithotripter type (odds ratio, 6.99; 95% confidence interval, 1.56 to 31.33; p<0.01) and main pancreatic duct stricture (odds ratio, 2.87; 95% confidence interval, 1.27 to 6.45; p<0.01) were significant factors for ESWL fragmentation.
Conclusions
The SLX F2 showed high performance in fragmenting the pancreatic duct stones.In addition, endoscopic adjunctive treatment improved the overall success rate of the procedure. The improved ESWL lithotripter has many advantages for patients undergoing pancreatic lithotripsy treatment.
10.Peroral pancreatoscopy with videoscopy and narrow-band imaging in intraductal papillary mucinous neoplasms with dilatation of the main pancreatic duct
Yui KISHIMOTO ; Naoki OKANO ; Ken ITO ; Kensuke TAKUMA ; Seiichi HARA ; Susumu IWASAKI ; Kensuke YOSHIMOTO ; Yuto YAMADA ; Koji WATANABE ; Yusuke KIMURA ; Hiroki NAKAGAWA ; Yoshinori IGARASHI
Clinical Endoscopy 2023;56(2):261-261